MARKET

ATNM

ATNM

ACTINIUM PHARMAC
AMEX

Real-time Quotes | Nasdaq Last Sale

8.22
-0.19
-2.26%
Closed 19:16 01/26 EST
OPEN
8.41
PREV CLOSE
8.41
HIGH
8.44
LOW
8.17
VOLUME
510.73K
TURNOVER
--
52 WEEK HIGH
19.47
52 WEEK LOW
4.710
MARKET CAP
111.68M
P/E (TTM)
-3.1782
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The alpha emitter market is expected to witness a healthy CAGR of 36.7% during the forecast period (2020 - 2025)
New York, Jan 20, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Alpha...
GlobeNewswire · 6d ago
Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that members of its executive team will participate in a fireside chat at the B. Riley Oncology Investor Conference, which is being held virtually from January 20th to 21st. ...
PR Newswire · 6d ago
How New Product Releases will Impact Radioimmunotherapy Treatment Market?
Jan 19, 2021 (MARKITWIRED via COMTEX) -- The business report depicts the present scenario of the worldwide Radioimmunotherapy Treatment market in terms of...
Markitwired · 01/19 10:13
William Blair Sticks to Its Buy Rating for Actinium Pharmaceuticals (ATNM)
In a report issued on January 13, Andy Hsieh from William Blair reiterated a Buy rating on Actinium Pharmaceuticals (ATNM). The company's shares closed
SmarterAnalyst · 01/15 18:15
Actinium, Astellas in research pact for radiotherapies
Actinium Pharmaceuticals (ATNM) has announced a research collaboration with Astellas Pharma (ALPMF) for the development of targeted radiotherapies using its Antibody Warhead Enabling ((AWE)) technology platform.Under this agreement, Actinium will
Seekingalpha · 01/13 12:43
Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
, /PRNewswire/ --  (NYSE AMERICAN: ATNM) ("Actinium") today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas") to develop novel targeted radiotherapies using its Antibody Warhead Enabling (AWE) technology platform.  Und...
PR Newswire - PRF · 01/13 12:00
Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas") to develop novel targeted radiotherapies using its Antibody Warhead Enabling (AWE) technology pla...
PR Newswire · 01/13 12:00
Global Hodgkin’s Lymphoma Treatment Market Trends, Analysis by Growth, Product Scope, Company Profiles, Business Overview, Opportunities | Expansions Plans till 2023
Jan 11, 2021 (The Expresswire) -- The “Hodgkin’s Lymphoma Treatment Market” report offers important information on the business overview, market trends,...
The Express Wire · 01/11 06:22
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATNM. Analyze the recent business situations of ACTINIUM PHARMAC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATNM stock price target is 38.75 with a high estimate of 65.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 23.40M
% Owned: 172.20%
Shares Outstanding: 13.59M
TypeInstitutionsShares
Increased
10
5.54M
New
5
10.91M
Decreased
6
1.59M
Sold Out
5
306.41K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.91%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Chairman/Chief Executive Officer/Director
Sandesh Seth
Chief Financial Officer/Chief Accounting Officer
Steve O'Loughlin
Chief Scientific Officer
Dale Ludwig
Other
Mark Berger
Vice President
Robert Daly
Lead Director/Independent Director
C. David Nicholson
Vice President
Steven Price
Independent Director
Jeffrey Chell
Independent Director
Ajit Shetty
Vice President
Vijay Reddy
Independent Director
Richard Steinhart
Vice President
Jehan Rowlands
Independent Director
C.David Nicholson
Independent Director
C. Nicholson
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About ATNM
Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.

Webull offers kinds of Actinium Pharmaceuticals Inc stock information, including AMEX:ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.